Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ligelizumab
- Development stage
- Phase 3
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Ligelizumab is a humanized IgG1 monoclonal antibody that targets immunoglobulin E (IgE). It binds specifically to an epitope in the Cε3 domain of IgE, neutralizing serum IgE and inhibiting its interaction with both high-affinity (FcεRI) and low-affinity (CD23/FcεRII) receptors. This blockade prevents the activation of allergic effector cells, reducing hypersensitivity reactions. Ligelizumab has been investigated primarily for chronic spontaneous urticaria (CSU), severe asthma, and food allergies. Compared to omalizumab, another anti-IgE antibody, ligelizumab exhibits higher affinity for free serum IgE and greater potency in blocking the IgE/FcεRI pathway[1][4][5][8]. The drug was developed by Novartis.
- Other names
- QGE031QGE-031QGE 031ligelizumab
02
Targets
IgE-CH3 (Immunoglobulin heavy constant epsilon Cε3 domain)
Beyond the preview
Go deeper on ligelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ligelizumab.